State of Tennessee, Department of Treasury
Position in KRYS — Krystal Biotech, Inc.
CIK 1587973
NASHVILLE, TN
Position in KRYS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$3,659,091
+$1,010,278 QoQ
Shares Held
9,845
-4.0% QoQ
Ownership
0.033%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#129
of 419 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in KRYS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026State of Tennessee, Department of Treasury holds $144,818,259 across 31 Biotechnology names. KRYS ranks #11 (2.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
93,032 | $46,211,785 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
46,766 | $29,160,471 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
181,244 | $6,414,225 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
24,074 | $5,801,111 | |
| 5 | CYTK |
Cytokinetics Inc
|
60,194 | $5,127,926 | |
| 6 | MRNA |
Moderna, Inc.
|
67,822 | $4,749,574 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
81,548 | $4,666,176 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
56,499 | $4,422,176 |
All Filings in KRYS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,659,091 | 9,845 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $2,648,813 | 10,254 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $2,512,982 | 10,193 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $1,962,660 | 11,118 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $1,505,324 | 10,951 | Shares | Sole | 2025-08-15 | |
| 2025-03-31 | $2,012,508 | 11,162 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $1,770,101 | 11,299 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $2,104,630 | 11,562 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||